SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on…

Catalyst Pharmaceuticals, Inc. · PRESS-RELEASE filed May 11, 2026 at 16:12 ET

At the news

BEARISHIMPACT 8/10

PRESS-RELEASE filed May 11, 2026 at 16:12 ET

Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus estimate of $0.64 EPS and $148.2M revenue. The company withdrew forward guidance and canceled its earnings call following a May 7 announcement, creating significant uncertainty despite strong underlying product revenue growth from FIRDAPSE and AGAMREE.

  • GAAP diluted EPS of $0.50 missed consensus estimate of $0.64 by 21.9%
  • Total revenue of $149.4M was slightly above consensus of $148.2M (beat by 0.8%)
  • Non-GAAP diluted EPS of $0.79 was reported, but Street consensus tracks GAAP EPS for pharma
  • FIRDAPSE revenue grew 18.1% YoY to $98.9M; AGAMREE grew 66.6% to $36.7M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access